Featured Research

from universities, journals, and other organizations

Just 4 Months Of Hormone Therapy Can Delay Prostate Cancer Growth By Up To 8 Years

Date:
January 7, 2008
Source:
American Society of Clinical Oncology
Summary:
Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years -- especially the development of bone metastases -- and increased survival in older men with potentially aggressive prostate cancer. This "neoadjuvant" hormonal therapy may allow men most at risk of developing bone metastases avoid long-term hormonal therapy later on.

Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years--especially the development of bone metastases--and increased survival in older men with potentially aggressive prostate cancer. This "neoadjuvant" hormonal therapy may allow men most at risk of developing bone metastases avoid long-term hormonal therapy later on. Furthermore, the short-term hormonal therapy did not increase the risk of cardiovascular disease--a potential side effect of long-term hormonal therapy.

Related Articles


Hormonal therapy--called androgen deprivation therapy (ADT)--lowers levels of cancer-fueling testosterone in the blood. It is an important treatment option for men with prostate cancer that continues to progress despite initial treatment with surgery, radiation therapy, or chemotherapy, but has been associated with side effects such as bone loss, osteoporosis, depression and an increase in cardiovascular risk factors (including blood lipids, abdominal obesity and a syndrome associated with diabetes).

"This study demonstrates that the benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks," said lead author Mack Roach III, MD, professor and chair of radiation oncology and professor of urology at the University of California, San Francisco. "While four months of hormonal therapy isn't enough to cause significant side effects, we found that it can delay the development of bone metastasis by as many as eight years, which is very significant."

Starting in 1987, Radiation Therapy Oncology Group researchers studied 224 men with high-risk prostate cancer who received ADT (goserelin and flutamide) before and concurrent with external beam radiation therapy, and 232 men with the disease who received radiation therapy alone. After 13 years of follow up, they found better 10-year disease-specific death rates (the rate of death from prostate cancer) for men who received ADT plus radiation (23 percent versus 36 percent of the radiation-only group), disease metastasis rates (35 percent versus 47 percent), disease-free survival (the percentage of men free of cancer at 10 years; 11 percent versus 3 percent) and biochemical failure rates (a rise in PSA levels; 65 percent versus 80 percent).

Among men who received neoadjuvant hormonal therapy, there was up to an eight-year delay in the time it took 40 percent of patients to develop bone metastases compared with men receiving radiation alone. Men who develop bone metastases often require long-term hormonal therapy, which can increase their risk for side effects. "So by taking a little bit of hormonal therapy early, patients may avoid having to take a lot of it later," added Dr. Roach.

Fatal cardiac events occurred in 12 percent of patients in the ADT group compared with 9 percent of the radiation-only group--a difference that was not statistically significant.

The study is being published online January 2 in the Journal of Clinical Oncology.

Journal article: "Short-Term Neoadjuvant Deprivation Therapy and External Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610 a Phase III Prospective Randomized Trial." Mack Roach, III, et al, University of California San Francisco, San Francisco, CA.


Story Source:

The above story is based on materials provided by American Society of Clinical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

American Society of Clinical Oncology. "Just 4 Months Of Hormone Therapy Can Delay Prostate Cancer Growth By Up To 8 Years." ScienceDaily. ScienceDaily, 7 January 2008. <www.sciencedaily.com/releases/2008/01/080102222947.htm>.
American Society of Clinical Oncology. (2008, January 7). Just 4 Months Of Hormone Therapy Can Delay Prostate Cancer Growth By Up To 8 Years. ScienceDaily. Retrieved April 1, 2015 from www.sciencedaily.com/releases/2008/01/080102222947.htm
American Society of Clinical Oncology. "Just 4 Months Of Hormone Therapy Can Delay Prostate Cancer Growth By Up To 8 Years." ScienceDaily. www.sciencedaily.com/releases/2008/01/080102222947.htm (accessed April 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, April 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Sees Resurgence of Drug Trafficking as Ebola Wanes

Liberia Sees Resurgence of Drug Trafficking as Ebola Wanes

AFP (Apr. 1, 2015) The governments of Liberia and Sierra Leone have been busy fighting the menace created by the deadly Ebola virus, but illicit drug lords have taken advantage of the situation to advance the drug trade. Duration: 01:12 Video provided by AFP
Powered by NewsLook.com
Stigma Stalks India's Leprosy Sufferers as Disease Returns

Stigma Stalks India's Leprosy Sufferers as Disease Returns

AFP (Apr. 1, 2015) The Indian government declared victory over leprosy in 2005, but the disease is making a comeback in some parts of the country, with more than a hundred thousand lepers still living in colonies, shunned from society. Duration: 02:41 Video provided by AFP
Powered by NewsLook.com
7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins